Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
34.7M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
17.6M
-
Shares change
-
+739K
-
Total reported value, excl. options
-
$517M
-
Value change
-
+$7.33M
-
Put/Call ratio
-
0.73
-
Number of buys
-
46
-
Number of sells
-
-53
-
Price
-
$29.33
Significant Holders of IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) as of Q4 2021
131 filings reported holding IGMS - IGM Biosciences, Inc. - Common Stock, par value $0.01 per share as of Q4 2021.
IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.6M shares
of 34.7M outstanding shares and own 50.79% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (3.33M shares), BAKER BROS. ADVISORS LP (3.16M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.37M shares), Artal Group S.A. (1.5M shares), ALKEON CAPITAL MANAGEMENT LLC (939K shares), PICTET ASSET MANAGEMENT SA (935K shares), STATE STREET CORP (732K shares), BlackRock Inc. (677K shares), Cormorant Asset Management, LP (500K shares), and VANGUARD GROUP INC (415K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.